- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injection of galcanezumab.
Migraine in adults: prophylaxis
Prophylaxis of migraine in adults who have at least 4 migraine days per month.
Initial loading dose: 240mg
Maintenance dose: 120mg once a month
Additional Dosage Information
If a missed dose occurs, inject as soon as possible and then continue with monthly dosing.
Galcanezumab is for subcutaneous injection only.
Children under 18 years
Precautions and Warnings
Patients over 65 years
Severe cardiovascular disorder
Severe hepatic impairment
Severe renal impairment
Advise ability to drive/operate machinery may be affected by side effects
Treatment to be initiated by specialist
Record name and batch number of administered product
Self-admin. - only if adequately trained and have access to expert advice
Assess benefit within 3 months and evaluate continued need regularly
Discontinue if severe hypersensitivity reactions occur
Pregnancy and Lactation
Galcanezumab is contraindicated during pregnancy.
The manufacturer suggests it is preferable to avoid using galcanezumab during pregnancy.
At the time of writing there is limited published data regarding the use of galcanezumab during pregnancy. Human immunoglobulin is known to cross the placenta. Animal studies do not indicate reproductive toxicity.
Use galcanezumab with caution during breastfeeding.
The manufacturer advises caution if galcanezumab is used when breastfeeding.
It is unknown whether galcanezumab is excreted in human milk. Human IgG is excreted into the milk during the first few days after birth although levels decrease soon afterwards, a risk to a breastfed infant cannot be excluded. The use of galcanezumab could be considered after this period if clinically needed. Effects on exposed infants are unknown.
Bruising at injection site
Erythema at injection site
Local pain (injection site)
Local reaction at injection site
Swelling (injection site)
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: November 2021
Summary of Product Characteristics: Emgality 120mg solution for injection in pre-filled pen. Eli Lilly and Company Ltd. Revised September 2021.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.